ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 77 filers reported holding ONCOCYTE CORP in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $1,000 | -98.1% | 573 | -98.4% | 0.00% | – |
Q1 2022 | $54,000 | -30.8% | 36,073 | 0.0% | 0.00% | – |
Q4 2021 | $78,000 | -39.5% | 36,073 | -0.4% | 0.00% | – |
Q3 2021 | $129,000 | -53.8% | 36,212 | -25.6% | 0.00% | – |
Q2 2021 | $279,000 | +11.6% | 48,693 | +1.2% | 0.00% | – |
Q1 2021 | $250,000 | +166.0% | 48,100 | +22.1% | 0.00% | – |
Q4 2020 | $94,000 | +70.9% | 39,400 | 0.0% | 0.00% | – |
Q3 2020 | $55,000 | -26.7% | 39,400 | 0.0% | 0.00% | – |
Q2 2020 | $75,000 | +200.0% | 39,400 | +294.0% | 0.00% | – |
Q1 2020 | $25,000 | +8.7% | 10,000 | 0.0% | 0.00% | – |
Q4 2019 | $23,000 | +9.5% | 10,000 | 0.0% | 0.00% | – |
Q3 2019 | $21,000 | -79.0% | 10,000 | -75.0% | 0.00% | – |
Q2 2019 | $100,000 | +203.0% | 40,000 | +154.8% | 0.00% | – |
Q1 2018 | $33,000 | -54.8% | 15,700 | 0.0% | 0.00% | – |
Q4 2017 | $73,000 | -38.7% | 15,700 | 0.0% | 0.00% | – |
Q3 2017 | $119,000 | +45.1% | 15,700 | 0.0% | 0.00% | – |
Q2 2017 | $82,000 | +30.2% | 15,700 | +15.7% | 0.00% | – |
Q1 2016 | $63,000 | – | 13,574 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 23,353,697 | $17,048,000 | 1.30% |
AWM Investment Company, Inc. | 7,746,557 | $5,655,000 | 0.86% |
PURA VIDA INVESTMENTS, LLC | 18,056,274 | $13,181,000 | 0.76% |
Defender Capital, LLC. | 2,551,980 | $1,883,000 | 0.74% |
Penbrook Management LLC | 563,350 | $411,000 | 0.35% |
ACT CAPITAL MANAGEMENT, LLC | 330,000 | $241,000 | 0.33% |
CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $55,000 | 0.04% |
Fort Sheridan Advisors LLC | 135,000 | $99,000 | 0.03% |
Orbimed Advisors | 1,882,768 | $1,374,000 | 0.03% |
WEALTH EFFECTS LLC | 51,000 | $37,000 | 0.02% |